We are pleased to inform that our company is participating in the research project under the biggest EU Research and Innovation programme - "Horizon 2020".
2KMM is a member of an international consortium, coordinated by the Medical University of Zagreb. The consortium consists of 13 partners from 6 European Union member states, assembled to conduct a Phase II, randomized, clinical trial project: Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain with the acronym: OSTEOproSPINE.
In this 5 year-long trial with the budget of 6 million EUR, 2KMM will be responsible for the set-up and hosting of an electronic CRF based on our data collection platform - GoResearch™, data management and biostatistics. The start of the project is scheduled for January 2018.
More information on Osteogrow -- an innovative and unique approach towards safe, effective and inexpensive bone regeneration therapy can be found at http://osteogrow.eu/.